Post-registration of medicines – opportunities and challenges
Unraveling the Abbreviated Development Path
Publication of the Public Consultation for the review of RDC 200 - what is new?
NEW REGULATORY FRAMEWORK OF API
What are the new expectations for the development of incremental products and medicines?
INCREMENTAL INNOVATION: How to prepare for the changes that will come with the revision of RDC 200
Why are 24% of drug registrations still rejected?
Cannabis: challenges and opportunities
NEW API REGULATORY FRAMEWORK: Will ANVISA and international manufacturers be prepared?
What is important about the new regulatory framework for good manufacturing practices?
